EUVIMEDEUVIMED entdecken
Open Access

Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N, SHH type and poor survival independent of treatment strategies

Marthe Sönksen iD, Denise Obrecht-Sturm iD, Pablo Hernáiz Driever, Axel Sauerbrey, Norbert Graf, Udo Kontny, Christian Reimann, Mina Langhein, Uwe R Kordes, Rudolf Schwarz, Tobias Obser, Felix Boschann und 6 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae111 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Marthe Sönksen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Medulloblastoma, Fanconi Anemia, Cerebellar Neoplasms, Hedgehog Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: German Childhood Cancer Foundation, Clinician Scientist Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The outcome of children with medulloblastoma (MB) and Fanconi Anemia (FA), an inherited DNA repair deficiency, has not been described systematically. Treatment is complicated by high vulnerability to treatment-associated side effects, yet structured data are lacking. This study aims to give a comprehensive overview of clinical and molecular characteristics of pediatric FA MB patients.

Methods

Clinical data including detailed information on the treatment and toxicities of 6 previously unreported FA MB patients were supplemented with data of 16 published cases.

Results

We identified 22 cases of children with FA and MB with clinical data available. All MBs with subgroup reporting were SHH-activated (n = 9), confirmed by methylation profiling in 5 patients. FA MB patients exclusively belonged to complementation groups FA-D1 (n = 16) or FA-N (n = 3). Patients were treated with postoperative chemotherapy only (50%) or radiotherapy (RT) ± chemotherapy (27%). Of 23% did not receive adjuvant therapy. Excessive treatment-related toxicities were frequent. Severe hematological toxicity occurred in 91% of patients treated with alkylating chemotherapy, while non-alkylating agents and RT were less toxic. Median overall survival (OS) was 1 year (95%CI: 0.3–1.8). 1-year-progression-free-survival (PFS) was 26.3% ± 10.1% and 1-year-OS was 42.1% ± 11.3%. Adjuvant therapy prolonged survival (1y-OS/1y-PFS 0%/0% without adjuvant therapy vs. 53.3% ± 12.9%/33.3 ± 12.2% with adjuvant therapy, P = .006/P = .086).

Conclusions

MB in FA patients is strongly associated with SHH activation and FA-D1/FA-N. Despite the dismal prognosis, adjuvant therapy may prolong survival. Non-alkylating chemotherapy and RT are feasible in selected patients with careful monitoring of toxicities and dose adjustments. Curative therapy for FA MB-SHH remains an unmet medical need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MedulloblastomaFanconi AnemiaCerebellar NeoplasmsHedgehog ProteinsHumansMaleFemaleChildChild, PreschoolAdolescentSurvival RatePrognosisInfantFollow-Up StudiesCombined Modality Therapy

Stichwörter der Autor:innen

FA-D1FA-NFanconi anemiamedulloblastomatumor predisposition

Substanzen

Hedgehog ProteinsSHH protein, human

Autor:innen und Institutionen

  • Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Pediatric Oncology and Hematology, Berlin, Germany.
  • Pediatric Clinics, Helios Hospital, Erfurt, Germany.
  • Department of Pediatric Oncology and Hematology, Saarland University, Homburg, Germany.
  • Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.
  • Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.

ORCID-Profile: Marthe Sönksen, Denise Obrecht-Sturm, Ulrich Schüller, Martin Mynarek, Stefan Rutkowski

Förderung

  • German Childhood Cancer Foundation
  • Clinician Scientist Program

Zitieren

APA

Sönksen, M., Obrecht-Sturm, D., Hernáiz Driever, P., Sauerbrey, A., Graf, N., Kontny, U., Reimann, C., Langhein, M., Kordes, U. R., Schwarz, R., Obser, T., Boschann, F., Schüller, U., Altendorf, L., Goschzik, T., Pietsch, T., Mynarek, M., & Rutkowski, S. (2024). Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N, SHH type and poor survival independent of treatment strategies. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae111

Vancouver

Sönksen M, Obrecht-Sturm D, Hernáiz Driever P, Sauerbrey A, Graf N, Kontny U, et al. Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N, SHH type and poor survival independent of treatment strategies. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae111

BibTeX
@article{Snksen2024,
  author = {Sönksen, Marthe and Obrecht-Sturm, Denise and Hernáiz Driever, Pablo and Sauerbrey, Axel and Graf, Norbert and Kontny, Udo and Reimann, Christian and Langhein, Mina and Kordes, Uwe R and Schwarz, Rudolf and Obser, Tobias and Boschann, Felix and Schüller, Ulrich and Altendorf, Lea and Goschzik, Tobias and Pietsch, Torsten and Mynarek, Martin and Rutkowski, Stefan},
  title = {Medulloblastoma in children with Fanconi anemia: Association with FA-D1/FA-N, SHH type and poor survival independent of treatment strategies},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae111}
}
Kostenlos starten →